For Oncor, the luxury of R&D still exists

While many biotech companies are thinking about cutting their R&D budgets to conserve scarce resources, those with strong cash positions have the luxury of expanding their pipelines and building for the future.

Driven by the outpouring of gene discoveries from the human genome project, Oncor Inc. decided to increase its 1993

Read the full 516 word article

How to gain access

Continue reading with a
two-week free trial.